Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen vaccine for clear cell renal cell carcinoma
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
A personalized neoantigen vaccine designed to treat clear cell renal cell carcinoma (ccRCC). This therapeutic vaccine is custom-built for each patient by analyzing the DNA and RNA from their tumor to identify unique mutated proteins (neoantigens) present only in the cancer cells. The vaccine then trains the patient's immune system, specifically T cells, to recognize and destroy these neoantigens, thereby targeting and eliminating remaining cancer cells after surgery. This approach aims to "steer" the immune system towards tumor-specific targets, offering a more precise and potentially less toxic treatment compared to general immunotherapies. Early phase 1 clinical trials have shown promising results in patients with high-risk stage III or IV ccRCC, demonstrating robust anti-cancer immune responses and prolonged cancer-free survival with manageable side effects. The research has been led by institutions such as Yale Cancer Center and Dana-Farber Cancer Institute.
- Other names
- personalized cancer vaccineneoantigen vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Personalized neoantigen vaccine for clear cell renal cell carcinoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen vaccine for clear cell renal cell carcinoma.